Skip Navigation



JAC Advance Access published online on January 23, 2008
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkm492
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
61/3/595    most recent
dkm492v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pillar, C. M.
Right arrow Articles by Sahm, D. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pillar, C. M.
Right arrow Articles by Sahm, D. F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent Gram-positive and Gram-negative isolates of European origin

Chris M. Pillar, Mohana K. Aranza, Dineshchandra Shah and Daniel F. Sahm*

Eurofins Medinet, Inc., Anti-Infective Services, 13665 Dulles Technology Drive, Herndon, VA 20171, USA

Received 17 July 2007; returned 23 September 2007; revised 21 November 2007; accepted 26 November 2007

* Corresponding author. Tel: +1-703-480-2500; Fax: +1-703-480-2670; E-mail: dan.sahm{at}eurofinsmedinet.com

Objectives: To determine the in vitro activity profile of ceftobiprole, a pyrrolidinone cephalosporin with activity against methicillin-resistant Staphylococcus aureus (MRSA), for use as a contemporary baseline to help detect any changes in its activity profile throughout the course of clinical development and use.

Methods: MICs were determined by broth microdilution testing for ceftobiprole and comparators against 6680 isolates [1201 S. aureus, 460 coagulase-negative staphylococci (CoNS), 526 Streptococcus pneumoniae, 1213 Escherichia coli, 854 Klebsiella pneumoniae, 443 Proteus mirabilis, 406 Enterobacter cloacae, 387 Citrobacter spp., 291 Serratia marcescens, 621 Pseudomonas aeruginosa and 278 Acinetobacter spp.] from 31 sites in 12 countries.

Results: Ceftobiprole activity against MRSA (MIC90 2 mg/L) was 4-fold less than the activity against methicillin-susceptible S. aureus (MIC90 0.5 mg/L) and a similar trend was observed for methicillin-resistant CoNS (MIC90 2 mg/L) and methicillin-susceptible CoNS (MIC90 0.25 mg/L). Activity against S. pneumoniae (MIC90s: penicillin-susceptible, 0.015 mg/L; -intermediate, 0.25 mg/L; -resistant, 0.5 mg/L) was comparable to that of ceftriaxone. Ceftobiprole activity against Enterobacteriaceae (MIC90s: ceftazidime-susceptible, 0.12 mg/L; non-susceptible, >32 mg/L), P. aeruginosa (MIC90s: ceftazidime-susceptible, 8 mg/L, non-susceptible, >32 mg/L) and Acinetobacter spp. (MIC90: >32 mg/L for imipenem-susceptible and non-susceptible) was comparable to that of cefepime. As with cefepime, ceftobiprole activity was decreased among cephalosporin-resistant isolates of Gram-negative bacilli [extended-spectrum β-lactamase (ESBL) or non-ESBL mediated].

Conclusions: Ceftobiprole demonstrated potent in vitro activity against MRSA and showed activity against key Gram-negative bacilli comparable to that of cefepime. Given this broad spectrum of activity, ceftobiprole appears well suited for development and use in the treatment of a variety of healthcare-associated infections.

Key Words: susceptibility tests , MICs , microbiology


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
S. N. Patel, D. R. Pillai, S. Pong-Porter, A. McGeer, K. Green, and D. E. Low
In vitro activity of ceftaroline, ceftobiprole and cethromycin against clinical isolates of Streptococcus pneumoniae collected from across Canada between 2003 and 2008
J. Antimicrob. Chemother., September 1, 2009; 64(3): 659 - 660.
[Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
E. Z. Baum, S. M. Crespo-Carbone, B. J. Morrow, T. A. Davies, B. D. Foleno, W. He, A. M. Queenan, and K. Bush
Effect of MexXY Overexpression on Ceftobiprole Susceptibility in Pseudomonas aeruginosa
Antimicrob. Agents Chemother., July 1, 2009; 53(7): 2785 - 2790.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
D. F. J. Brown, R. Hope, D. M. Livermore, G. Brick, K. Broughton, R. C. George, R. Reynolds, and on behalf of the BSAC Working Parties on Resistanc
Non-susceptibility trends among enterococci and non-pneumococcal streptococci from bacteraemias in the UK and Ireland, 2001-06
J. Antimicrob. Chemother., November 1, 2008; 62(suppl_2): ii75 - ii85.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
A. Walkty, M. DeCorby, K. Nichol, J. A. Karlowsky, D. J. Hoban, G. G. Zhanel, and on behalf of the Canadian Antimicrobial Resistance
In vitro activity of ceftobiprole against clinical isolates of Pseudomonas aeruginosa obtained from Canadian intensive care unit (ICU) patients as part of the CAN-ICU Study
J. Antimicrob. Chemother., July 1, 2008; 62(1): 206 - 208.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.